Currently, there are 1.20B common shares owned by the public and among those 1.17B shares have been available to trade.
The company’s stock has a 5-day price change of -1.44% and -0.26% over the past three months. VTRS shares are trading 7.76% year to date (YTD), with the 12-month market performance up to 25.48% higher. It has a 12-month low price of $8.74 and touched a high of $13.62 over the same period. VTRS has an average intraday trading volume of 7.90 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 1.23%, 0.56%, and 1.15% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Viatris Inc (NASDAQ: VTRS) shares accounts for 82.06% of the company’s 1.20B shares outstanding.
It has a market capitalization of $13.93B and a beta (3y monthly) value of 0.93. The earnings-per-share (ttm) stands at -$0.54. Price movements for the stock have been influenced by the stock’s volatility, which stands at 1.76% over the week and 2.03% over the month.
Earnings per share for the fiscal year are expected to decrease by -8.94%, and 0.92% over the next financial year. EPS should grow at an annualized rate of -3.41% over the next five years, compared to -41.87% over the past 5-year period.
Looking at the support for the VTRS, a number of firms have released research notes about the stock. Jefferies stated their Buy rating for the stock in a research note on July 19, 2024, with the firm’s price target at $15. BofA Securities coverage for the Viatris Inc (VTRS) stock in a research note released on October 23, 2023 offered a Underperform rating with a price target of $9. Barclays was of a view on June 23, 2023 that the stock is Underweight, while Barclays gave the stock Equal Weight rating on April 24, 2023, issuing a price target of $11. BMO Capital Markets on their part issued Market Perform rating on February 17, 2023.
